62 research outputs found

    Data from: The direction aftereffect is a global motion phenomenon

    No full text
    Prior experience influences visual perception. For example, extended viewing of a moving stimulus results in the misperception of a subsequent stimulus’s motion direction – the direction aftereffect (DAE). There has been an on-going debate regarding the locus of the neural mechanisms underlying the DAE. We know the mechanisms are cortical, but there is uncertainty about where in the visual cortex they are located – at relatively early local motion processing stages, or at later global motion stages. We used a unikinetic plaid as an adapting stimulus, then measured the DAE experienced with a drifting random dot test stimulus. A unikinetic plaid comprises a static grating superimposed on a drifting grating of a different orientation. Observers cannot see the true motion direction of the moving component; instead they see pattern motion running parallel to the static component. The pattern motion of unikinetic plaids is encoded at the global processing level – specifically, in areas MT and MST – and the local motion component is encoded earlier. We measured the direction aftereffect as a function of the plaid’s local and pattern motion directions. The DAE was induced by the plaid’s pattern motion, but not by its component motion. This points to the neural mechanisms underlying the DAE being located at the global motion processing level, and no earlier than area MT

    [The effect of low-dose hydrocortisone on requirement of norepinephrine and lactate clearance in patients with refractory septic shock].

    No full text

    Alirocumab and cardiovascular outcomes after acute coronary syndrome

    No full text
    BACKGROUN

    Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

    No full text
    BACKGROUN

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text

    Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

    No full text

    Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

    No full text

    Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    No full text
    • …
    corecore